journal
https://read.qxmd.com/read/33091364/use-of-adenovirus-type-5-vectored-vaccines-a-cautionary-tale
#1
LETTER
Susan P Buchbinder, M Juliana McElrath, Carl Dieffenbach, Lawrence Corey
No abstract text is available yet for this article.
October 19, 2020: Lancet
https://read.qxmd.com/read/33091363/science-misuse-and-polarised-political-narratives-in-the-covid-19-response
#2
LETTER
Rômulo Paes-Sousa, Christopher Millett, Rudi Rocha, Mauricio L Barreto, Thomas Hone
No abstract text is available yet for this article.
October 19, 2020: Lancet
https://read.qxmd.com/read/33091362/department-of-error
#3
(no author information available yet)
No abstract text is available yet for this article.
October 19, 2020: Lancet
https://read.qxmd.com/read/33091361/psychoanalysis-in-combatting-mass-non-adherence-to-medical-advice
#4
LETTER
Austin Ratner, Nisarg Gandhi
No abstract text is available yet for this article.
October 19, 2020: Lancet
https://read.qxmd.com/read/33091360/long-term-efficacy-and-safety-of-drug-coated-balloons-versus-drug-eluting-stents-for-small-coronary-artery-disease-basket-small-2-3-year-follow-up-of-a-randomised-non-inferiority-trial
#5
Raban V Jeger, Ahmed Farah, Marc-Alexander Ohlow, Norman Mangner, Sven Möbius-Winkler, Daniel Weilenmann, Jochen Wöhrle, Georg Stachel, Sinisa Markovic, Gregor Leibundgut, Peter Rickenbacher, Stefan Osswald, Marco Cattaneo, Nicole Gilgen, Christoph Kaiser, Bruno Scheller
BACKGROUND: In the treatment of de-novo coronary small vessel disease, drug-coated balloons (DCBs) are non-inferior to drug-eluting stents (DESs) regarding clinical outcome up to 12 months, but data beyond 1 year is sparse. We aimed to test the long-term efficacy and safety of DCBs regarding clinical endpoints in an all-comer population undergoing percutaneous coronary intervention. METHODS: In this prespecified long-term follow-up of a multicentre, randomised, open-label, non-inferiority trial, patients from 14 clinical sites in Germany, Switzerland, and Austria with de-novo lesions in coronary vessels <3 mm and an indication for percutaneous coronary intervention were randomly assigned 1:1 to DCB or second-generation DES and followed over 3 years for major adverse cardiac events (ie, cardiac death, non-fatal myocardial infarction, and target-vessel revascularisation [TVR]), all-cause death, probable or definite stent thrombosis, and major bleeding (Bleeding Academic Research Consortium bleeding type 3-5)...
October 19, 2020: Lancet
https://read.qxmd.com/read/33091359/ending-support-for-medical-organisations-puts-the-world-at-risk
#6
LETTER
Adrian Baranchuk, Alvaro Sosa Liprandi, Fernando Wyss, Daniel Pineiro
No abstract text is available yet for this article.
October 19, 2020: Lancet
https://read.qxmd.com/read/33091358/in-the-2020-us-election-we-can-choose-a-just-future
#7
Rhea W Boyd, Nancy Krieger, Camara Phyllis Jones
No abstract text is available yet for this article.
October 19, 2020: Lancet
https://read.qxmd.com/read/33075305/fighting-racism-in-schools-of-public-health
#8
LETTER
Lisa Wandschneider, Yudit Namer, Nurcan Akbulut, Oliver Razum
No abstract text is available yet for this article.
October 16, 2020: Lancet
https://read.qxmd.com/read/33075304/unnecessary-obstacles-to-covid-19-mass-testing
#9
LETTER
Julian Peto, David J Hunter, Elio Riboli, Julian L Griffin
No abstract text is available yet for this article.
October 16, 2020: Lancet
https://read.qxmd.com/read/33075303/paho-needs-reform-and-awareness-not-solidarity-and-funding
#10
LETTER
Michelle M Amri
No abstract text is available yet for this article.
October 16, 2020: Lancet
https://read.qxmd.com/read/33069278/the-lombardy-region-of-italy-launches-the-first-investigative-covid-19-commission
#11
LETTER
Michele Usuelli
No abstract text is available yet for this article.
October 15, 2020: Lancet
https://read.qxmd.com/read/33069277/scientific-consensus-on-the-covid-19-pandemic-we-need-to-act-now
#12
LETTER
Nisreen A Alwan, Rochelle Ann Burgess, Simon Ashworth, Rupert Beale, Nahid Bhadelia, Debby Bogaert, Jennifer Dowd, Isabella Eckerle, Lynn R Goldman, Trisha Greenhalgh, Deepti Gurdasani, Adam Hamdy, William P Hanage, Emma B Hodcroft, Zoë Hyde, Paul Kellam, Michelle Kelly-Irving, Florian Krammer, Marc Lipsitch, Alan McNally, Martin McKee, Ali Nouri, Dominic Pimenta, Viola Priesemann, Harry Rutter, Joshua Silver, Devi Sridhar, Charles Swanton, Rochelle P Walensky, Gavin Yamey, Hisham Ziauddeen
No abstract text is available yet for this article.
October 15, 2020: Lancet
https://read.qxmd.com/read/33065036/nursing-s-seat-at-the-research-roundtable
#13
LETTER
Bevin Cohen, Mary E Cooley, Tamryn F Gray, Lauri Linder, Janice Phillips, Angela Starkweather, Katherine A Yeager, Noah Zanville
No abstract text is available yet for this article.
October 13, 2020: Lancet
https://read.qxmd.com/read/33065035/efficacy-immunogenicity-and-safety-of-a-plant-derived-quadrivalent-virus-like-particle-influenza-vaccine-in-adults-18-64-years-and-older-adults-%C3%A2-65-years-two-multicentre-randomised-phase-3-trials
#14
Brian J Ward, Alexander Makarkov, Annie Séguin, Stéphane Pillet, Sonia Trépanier, Jiwanjeet Dhaliwall, Michael D Libman, Timo Vesikari, Nathalie Landry
BACKGROUND: Seasonal influenza remains a substantial public health threat despite the availability of egg-derived and other vaccines. Plant-based manufacturing might address some of the limitations of current vaccines. We describe two phase 3 efficacy studies of a recombinant quadrivalent virus-like particle (QVLP) influenza vaccine manufactured in plants, one in adults aged 18-64 years (the 18-64 study) and one in older people aged 65 years and older (the 65-plus study). METHODS: We did two randomised, observer-blind, multinational studies in the northern hemisphere in the 2017-18 (the 18-64 study) and 2018-19 (the 65-plus study) influenza seasons...
October 13, 2020: Lancet
https://read.qxmd.com/read/33065034/sars-cov-2-immunity-review-and-applications-to-phase-3-vaccine-candidates
#15
REVIEW
Gregory A Poland, Inna G Ovsyannikova, Richard B Kennedy
Understanding immune responses to severe acute respiratory syndrome coronavirus 2 is crucial to understanding disease pathogenesis and the usefulness of bridge therapies, such as hyperimmune globulin and convalescent human plasma, and to developing vaccines, antivirals, and monoclonal antibodies. A mere 11 months ago, the canvas we call COVID-19 was blank. Scientists around the world have worked collaboratively to fill in this blank canvas. In this Review, we discuss what is currently known about human humoral and cellular immune responses to severe acute respiratory syndrome coronavirus 2 and relate this knowledge to the COVID-19 vaccines currently in phase 3 clinical trials...
October 13, 2020: Lancet
https://read.qxmd.com/read/33065033/first-human-efficacy-study-of-a-plant-derived-influenza-vaccine
#16
John S Tregoning
No abstract text is available yet for this article.
October 13, 2020: Lancet
https://read.qxmd.com/read/33065032/the-2020-us-election-is-a-crucial-opportunity-to-advance-women-s-reproductive-rights
#17
Jeni Klugman
No abstract text is available yet for this article.
October 13, 2020: Lancet
https://read.qxmd.com/read/33065031/maternal-and-child-mortality-worsens-in-latin-america-and-the-caribbean
#18
LETTER
Arachu Castro
No abstract text is available yet for this article.
October 13, 2020: Lancet
https://read.qxmd.com/read/33058777/taking-pandemic-sequelae-seriously-from-the-russian-influenza-to-covid-19-long-haulers
#19
Mark Honigsbaum, Lakshmi Krishnan
No abstract text is available yet for this article.
October 12, 2020: Lancet
https://read.qxmd.com/read/33049223/irritable-bowel-syndrome
#20
REVIEW
Alexander C Ford, Ami D Sperber, Maura Corsetti, Michael Camilleri
Irritable bowel syndrome is a functional gastrointestinal disorder with symptoms including abdominal pain associated with a change in stool form or frequency. The condition affects between 5% and 10% of otherwise healthy individuals at any one point in time and, in most people, runs a relapsing and remitting course. The best described risk factor is acute enteric infection, but irritable bowel syndrome is also more common in people with psychological comorbidity and in young adult women than in the rest of the general population...
October 9, 2020: Lancet
journal
journal
20186
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"